Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tanezumab - Eli Lilly and Company/Pfizer

Next Previous
X
Search
Drug Profile

Tanezumab - Eli Lilly and Company/Pfizer

Alternative Names: PF-04383119; PF-4383119; Raylumis; RI-624; RN-624

Latest Information Update: 11 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company; Rinat Neuroscience
  • Developer Eli Lilly and Company; Pfizer
  • Class Analgesics; Monoclonal antibodies
  • Mechanism of Action Nerve growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Back pain; Cancer pain; Diabetic neuropathies; Musculoskeletal pain; Postherpetic neuralgia

Most Recent Events

  • 13 Apr 2024 Efficacy data from a phase II trial in Cancer pain presented at the 76th Annual Meeting of the American Academy of Neurology 2024 (AAN-2024)
  • 05 Jan 2022 Adverse events data of a phase III OA SAFETY STUDY in patients with Osteoarthritis (OA) presented at ACR Convergence 2021 (ACR/ARP-2021)
  • 05 Jan 2022 Pooled adverse events data from phase III trials in Osteoarthritis presented at ACR Convergence 2021 (ACR/ARP-2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top